Gastrointestinal infections

1630-1800hrs GMT

Chaired by: Marisa Lanzman, Senior Pharmacist – Microbiology & ITU, Royal Free London NHS Foundation Trust

Presenters:
Professor Mervyn Singer, Professor of Intensive Care Medicine at University College London, Chair of the International Sepsis Forum
Professor Mark Wilcox, Consultant / Head of Microbiology Research & Development / and Infection Lead of the Leeds NIHR Diagnostic Technologies Medical Technology and In Vitro Diagnostic Co-operative at Leeds Teaching Hospitals NHS Trust
Professor Stephan Gehring, Head of Paediatrics, University Medicine Mainz, Germany

Programme:

Welcome and setting the scene presentation Marisa Lanzman, Royal Free London
Presentation 1:
Intraabdominal sepsis – challenges and treatments, the current landscape
Professor Mervyn Singer, Professor of Intensive Care Medicine at University College London, Chair of the International Sepsis Forum
Presentation 2:
Clostridium Difficile – treatment advances
Professor Mark Wilcox, Consultant / Head of Microbiology Research & Development / and Infection Lead of the Leeds NIHR Diagnostic Technologies Medical Technology and In Vitro Diagnostic Co-operative at Leeds Teaching Hospitals NHS Trust
Presentation 3:
Title tbc
Professor Stephan Gehring, Head of Paediatrics, University Medicine Mainz, Germany
Panel discussion – all speakers 


Support For Delegates

For any Delegates joining our webinars, the following browsers are supported:

Desktop
Please use Chrome, Firefox, Safari and Edge.
Here are the minimum version requirements for each browser:
Microsoft Edge 83+
Chrome 83+
Firefox 77+
Safari (iPad) 13.5+
Safari (Mac) 13.1+

Mobile
Delegates joining a webinar via their mobile will be able to join directly through their Unique Join Link issued at registration.

Speakers

Professor Mark Wilcox, Consultant / Head of Microbiology Research & Development / and Infection Lead of the Leeds NIHR Diagnostic Technologies Medical Technology and In Vitro Diagnostic Co-operative at Leeds Teaching Hospitals NHS Trust

Mark has formerly been the Director of Infection Prevention (4 years), Infection Control Doctor (8 years), Clinical Director of Pathology (6 years) and Head of Microbiology (15 years) at LTHT.

Professor Wilcox is Chair of PHE’s Rapid Review Panel (reviews the utility of infection prevention & control products for the NHS), and is a member of the PHE’s Programme Board on Healthcare Associated Infection & Antimicrobial Resistance. Since the pandemic, he is a member of UK Scientific Advisory Group on Emergencies (SAGE, COVID-19; and chairs one of its subgroups on Nosocomial Infection), and a co-chair of DHSC’s UK Technical Validation Group for COVID-19 tests. He is a member of the Medical Research Council’s Infections and Immunity Board, and the Scientific Advisory Board for the EU Innovative Medicines Initiative’s COMBACTE-NET consortium. From 2017, he was seconded one day per week to NHS Improvement to support the delivery of the new national target to reduce healthcare associated Gram-negative blood stream infections in England. He was the Deputy Chair of the UK Department of Health’s Antimicrobial Resistance and Healthcare Associated Infection (ARHAI) Committee up until 2018.

He is an expert advisor to the Department of Health in England on healthcare associated infections (HCAIs), UK NICE (C. difficile management and antimicrobial evaluations project), the UK EPIC/NICE projects, the Health Technology Assessment (HTA) programme on Healthcare Associated Infection, the Wellcome Trust and CARB-X panel on novel antimicrobials, and the European Centre for Disease Control. He is a member of UK, European and US working groups on C. difficile infection, and is on the Editorial Boards of Clinical Infectious Diseases, Journal of Hospital Infection and Infectious Diseases in Clinical Practice. He has provided clinical advice as part of the FDA/EMA submissions for the approval of several novel antimicrobial agents, 1998-2016.

Professor Wilcox heads a Healthcare Associated Infection research team at the University of Leeds (hhttps://medicinehealth.leeds.ac.uk/
faculty-/dir-record/research-groups/905/healthcare-associated-infection-research-group
), comprising ~30 doctors, scientists and nurses; projects include multiple aspects of Clostridium difficile infection, diagnostics, antibiotic resistance and the gut microbiome, staphylococcal infection, and the clinical development of new antimicrobial agents. He has a track record of translational research (https://medicinehealth.leeds.ac.uk/
medicine/staff/3541/
professor-mark-wilcox
), including providing the basis of clinical advice to the NHS. He has been the Principal/UK Investigator for 15 clinical trials of new anti-infective drugs, 1999-2018, has carried out multiple NIHR portfolio studies on healthcare associated infection topics, and is currently supplying central laboratory services for several clinical trials of antimicrobial agents. He has authored >560 papers and published a number of books and chapters. He is co-editor of Antimicrobial Chemotherapy (5th/6th/7th Eds, 2007/12/15).

Marisa Lanzman, Senior Pharmacist – Microbiology & ITU, Royal Free London NHS Foundation Trust

Marisa Lanzman is an infection pharmacist at the Royal Free Hospital specialising in Antimicrobials and Intensive Care medicine.

She is a member of the NICE Managing Common Infections guidelines committee and the UKCPA Pharmacy Infection Network committee.

Her interests include Antimicrobial Stewardship in secondary care with a focus on training standards for pharmacists and the management of sepsis

Professor Mervyn Singer, Professor of Intensive Care Medicine at University College London, Chair of the International Sepsis Forum

Mervyn Singer is Professor of Intensive Care Medicine at University College London and past Chair of the International Sepsis Forum. He co-led the ‘Sepsis-3’ redefinitions task force (Singer et al. JAMA 2016) that moved the emphasis of sepsis away from the bug and more towards a dysregulated host response triggered by the infection. He has researched and published widely on sepsis, infection and antibiotic use (and abuse) in journals such as NEJM, Lancet and JAMA, covering a broad range of basic mechanistic, translational and clinical research. He also provides advice on clinical management of sepsis to various national and international bodies.